StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Evofem Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$472.00K. For fiscal 2025 it was -$1.99M. The highest annual figure on record is -$1.99M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.99M–
FY2024Dec 31, 2024-$3.89M–
FY2023Dec 31, 2023-$8.97M–
FY2022Dec 31, 2022-$70.41M–
FY2021Dec 31, 2021-$146.67M–
FY2020Dec 31, 2020-$104.83M–
FY2019Dec 31, 2019-$55.10M–
FY2018Dec 31, 2018-$56.50M–
FY2017Dec 31, 2017-$19.24M–
FY2016Dec 31, 2016-$16.25M–
FY2015Dec 31, 2015-$37.91M–
FY2014Dec 31, 2014-$9.57M–
FY2013Dec 31, 2013-$12.90M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.14M–
Q1 FY2026Mar 31, 2026$2.30M+310.9%
Q4 FY2025Dec 31, 2025$31.00K–
Q3 FY2025Sep 30, 2025$336.00K–
Q2 FY2025Jun 30, 2025-$2.92M–
Q1 FY2025Mar 31, 2025$560.00K+355.3%
Q4 FY2024Dec 31, 2024-$2.41M–
Q3 FY2024Sep 30, 2024-$459.00K–
Q2 FY2024Jun 30, 2024-$1.14M–
Q1 FY2024Mar 31, 2024$123.00K–
Q2 FY2023Jun 30, 2023-$1.49M–
Q1 FY2023Mar 31, 2023-$4.94M–
Q4 FY2022Dec 31, 2022-$6.53M–
Q3 FY2022Sep 30, 2022-$16.30M–
Q2 FY2022Jun 30, 2022-$26.66M–
Q1 FY2022Mar 31, 2022-$20.92M–
Q4 FY2021Dec 31, 2021-$21.27M–
Q3 FY2021Sep 30, 2021-$37.37M–
Q2 FY2021Jun 30, 2021-$53.58M–
Q1 FY2021Mar 31, 2021-$34.46M–
Q4 FY2020Dec 31, 2020-$39.08M–
Q3 FY2020Sep 30, 2020-$35.82M–
Q2 FY2020Jun 30, 2020-$15.05M–
Q1 FY2020Mar 31, 2020-$14.88M–
Q4 FY2019Dec 31, 2019-$13.45M–
Q3 FY2019Sep 30, 2019-$14.43M–
Q2 FY2019Jun 30, 2019-$19.55M–
Q1 FY2019Mar 31, 2019-$7.68M–
Q4 FY2018Dec 31, 2018-$10.25M–
Q3 FY2018Sep 30, 2018-$8.93M–
Q2 FY2018Jun 30, 2018-$19.19M–
Q1 FY2018Mar 31, 2018-$18.14M–
Q4 FY2017Dec 31, 2017-$4.95M–
Q3 FY2017Sep 30, 2017-$4.75M–
Q2 FY2017Jun 30, 2017-$3.47M–
Q1 FY2017Mar 31, 2017-$6.07M–
Q4 FY2016Dec 31, 2016-$2.89M–
Q3 FY2016Sep 30, 2016-$3.12M–
Q2 FY2016Jun 30, 2016-$2.64M–

More Evofem Biosciences figures

See a number that looks wrong?